News Articles and Montana BioScience Alliance Newsletters

MONTANA BIOSCIENCE ENTERPRISES IN THE NEWS

Gaize
|
September 5, 2024

Device developed by Missoula company Gaize (gaize.ai) could help to keep people safe at work and on the road.

C2M Beta
|
August 19, 2024

2M Beta is a 12-week program delivering the foundational and modern skills required to transform influential ideas into thriving businesses. With access to more professional expertise, more state-of-the-art technology and more community resources, C2M Beta was founded with the mission to connect local entrepreneurs to more!

Montana BioScience Alliance
|
July 25, 2024

A message from Board President Cynthia Tsai

SPI Pharma, Inc. a global leader in biopharmaceutical excipient and adjuvant systems, and Inimmune, Corp., a pioneering biotechnology company specializing in the discovery and development of innate immune modulators, announce an agreement in principle to create a strategic collaboration to develop and commercialize advanced adjuvant systems for vaccine development. This collaboration leverages Inimmune’s world-class expertise in adjuvant formulation and immunotherapeutics and SPI Pharma’s extensive manufacturing and global commercial capabilities.

National Institutes of Health — Rocky Mountain Laboratories
|
May 21, 2024

NIAID scientists and colleagues are investigating a potential treatment strategy against Lyme disease that would directly suppress Borrelia burgdorferi, the bacterium that causes the disease. If successful, their idea could reduce or end aggressive broad-spectrum antibiotic treatments that can be drawn-out and destroy the body’s helpful bacteria.

ARTICLES OF INTEREST

When her husband was undergoing cancer treatment, Cindy Perez of Southwest Ranches, Fla., learned about a new blood test that could help find early cancers. The 50-year-old said she felt fine, but her husband urged her to take the test anyway.

National Institutes of Health
|
March 26, 2024

Studies of interactions between two lab-generated monoclonal antibodies (mAbs) and an essential Epstein-Barr virus (EBV) protein have uncovered targets that could be exploited in designing treatments and vaccines for this extremely common virus.

BIO.News
|
January 30, 2024

As a new year begins in Congress, the Biotechnology Innovation Organization (BIO) is carrying over many of its legislative priorities from last year.

NIH National Institute on Aging
|
January 18, 2024

Administrative Supplements to Promote Diversity in Research and Development Small Businesses – SBIR/STTR

National Institutes of Health SEED
|
January 18, 2024

Contract Pre-solicitation for R&D that will contribute toward ARPA-H mission needs and SBIR program objectives.

NEWSLETTER

Newsletter
|
August 26, 2024

View the September 2024 Newsletter now!

Newsletter
|
July 25, 2024

View the Summer 2024 Newsletter now!